Mustang Bio (MBIO) Long-Term Debt Issuances (2016 - 2023)
Mustang Bio (MBIO) posted quarterly Long-Term Debt Issuances of $30.4 million for Q2 2023, up 201.25% year-over-year from $10.1 million in Q2 2022, and up 201.25% quarter-over-quarter from -$30.0 million in Q4 2022.
Mustang Bio (MBIO) Long-Term Debt Issuances (2016 - 2023) Analysis & Trends
Mustang Bio (MBIO) has reported Long-Term Debt Issuances for 6 consecutive years, with $30.4 million the latest figure, recorded in Q2 2023.
- In Q2 2023, Long-Term Debt Issuances rose 201.25% year-over-year to $30.4 million; the TTM figure through Sep 2024 stood at $30.4 million (up 8000.0% YoY), while the FY2023 annual figure was $30.4 million, changed N/A from the prior year.
- Long-Term Debt Issuances improved to $30.4 million in Q2 2023 per MBIO's latest filing, from -$30.0 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $30.4 million in Q2 2023 and bottomed at -$30.0 million in Q2 2022.
- Historically, Long-Term Debt Issuances has averaged $10.3 million across 4 years, with a median of $19.1 million in 2019.
- On a YoY basis, Long-Term Debt Issuances climbed as much as 201.25% in 2023 and fell as far as 201.25% in 2023.
- Mustang Bio's Long-Term Debt Issuances stood at $22.5 million in 2019, then fell by 30.0% to $15.8 million in 2020, then sank by 290.48% to -$30.0 million in 2022, then jumped by 201.25% to $30.4 million in 2023.
- Business Quant data shows MBIO's Long-Term Debt Issuances at $30.4 million in Q2 2023, -$30.0 million in Q4 2022, and $30.0 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 30.38 Mn |
| Jun 30, 2023 | 30.38 Mn |
| Dec 31, 2022 | -30.00 Mn |
| Dec 31, 2022 | -30.00 Mn |
| Sep 30, 2022 | 30.00 Mn |
| Sep 30, 2022 | 30.00 Mn |
| Jun 30, 2022 | -30.00 Mn |
| Jun 30, 2022 | -30.00 Mn |
| Mar 31, 2022 | 30.00 Mn |
| Mar 31, 2022 | 30.00 Mn |
| Dec 31, 2020 | 15.75 Mn |
| Dec 31, 2020 | 15.75 Mn |
| Jun 30, 2019 | 22.50 Mn |
| Jun 30, 2019 | 22.50 Mn |
| Mar 31, 2019 | 13.61 Mn |
| Mar 31, 2019 | 13.61 Mn |
| Mar 31, 2017 | 320,000.00 |
| Mar 31, 2017 | 320,000.00 |
| Dec 31, 2016 | -1.31 Mn |
| Dec 31, 2016 | -1.31 Mn |